<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152971</url>
  </required_header>
  <id_info>
    <org_study_id>1160.24</org_study_id>
    <nct_id>NCT00152971</nct_id>
  </id_info>
  <brief_title>Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement</brief_title>
  <official_title>A Phase III, Randomized, Parallel-group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day 1 Followed by 150 mg Day 2-completion, and 110 mg Day 1 Followed by 220 mg Day 2-completion) of Dabigatran Etexilate Administered Orally (Capsules), Compared to Enoxaparin 30 mg Twice a Day Subcutaneous for 12 - 15 Days in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Knee Replacement Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To determine the comparative efficacy and safety of two different doses (75mg day 1 followed
      by 150 mg day 2-completion, and 110 mg day 1 followed by 220 mg day 2-completion) of
      dabigatran administered orally (capsules), compared to enoxaparin 30 mg twice a day
      subcutaneous, in prevention of venous thromboembolism in patients with primary elective total
      knee replacement surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</measure>
    <time_frame>First administration until 12-15 days</time_frame>
    <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</measure>
    <time_frame>First administration until 12-15 days</time_frame>
    <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 12-15 days</time_frame>
    <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 12-15 days</time_frame>
    <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</measure>
    <time_frame>First administration until 12-15 days</time_frame>
    <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pulmonary Embolism During Treatment Period</measure>
    <time_frame>First administration until 12-15 days</time_frame>
    <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died During Treatment Period</measure>
    <time_frame>First administration until 12-15 days</time_frame>
    <description>All cause death, as adjudicated by the VTE events committee</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</measure>
    <time_frame>3 months</time_frame>
    <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</measure>
    <time_frame>First administration until 12-15 days</time_frame>
    <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2615</enrollment>
  <condition>Arthroplasty, Replacement, Knee</condition>
  <condition>Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Dabigatran Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose regimen taken once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dabigatran Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose regimen taken once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg subcutaneously twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Dose 1 - day 2 to completion</intervention_name>
    <description>low dose regimen taken once daily</description>
    <arm_group_label>Dabigatran Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Dose 1 - day 1</intervention_name>
    <description>low dose regimen taken once daily</description>
    <arm_group_label>Dabigatran Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Dose 2 - day 2 to completion</intervention_name>
    <description>high dose regimen taken once daily</description>
    <arm_group_label>Dabigatran Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Dose 2 - day 1</intervention_name>
    <description>high dose regimen taken once daily</description>
    <arm_group_label>Dabigatran Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>30 mg subcutaneously twice daily</description>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria INCLUSION CRITERIA

          1. Patients scheduled to undergo a primary, unilateral elective total knee repla cement.

          2. Male or female 18 years of age or older.

          3. Patients weighing at least 40 kg.

          4. Written informed consent prior to the start of study participation.

        Exclusion criteria EXCLUSION CRITERIA

          1. History of bleeding diathesis.

          2. Constitutional or acquired coagulation disorders that in the investigator's judgment
             puts the patient at excessive risk for bleeding.

          3. Major surgery or trauma (e.g. hip fracture) within the last 3 months.

          4. Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time
             of enrollment (investigator's judgment) or history of myocardial infarction within the
             last 3 months.

          5. Spinal or epidural anesthesia, for which more than 3 attempts (sticks) at placement
             were made, or the placement was traumatic.

             Please note that patients, who are not excluded under this criterion, are to have the
             catheter pulled at the completion of surgery.

          6. Any history of hemorrhagic stroke or any of the following intracranial pathologies:
             bleeding, neoplasm, arteriovenous (AV) malformation or aneurysm.

          7. History of VTE or pre-existing condition requiring anticoagulant therapy.

          8. Clinically relevant bleeding (e.g. gastrointestinal, pulmonary, intraocular or
             urogenital bleeding) within the last 6 months.

          9. Gastric or duodenal ulcer within the last 6 months.

         10. Liver disease expected to have any potential impact on survival (e.g. hepatitis B or
             C, cirrhosis, but not Gilbert's syndrome or hepatitis A with complete recovery).

         11. Elevated AST or ALT &gt;2x upper limit of normal, based on central lab results or local
             lab results within 1 month before enrollment.

         12. Known severe renal insufficiency (CrCl &lt; 30 mL/min). In order to determine patient
             inclusion/exclusion, creatinine clearance (CrCl) needs to be calculated only if serum
             creatinine is elevated or renal insufficiency is suspected.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.24.01074 Capstone Clinical Trials, Inc.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01079 West AL Research, Inc</name>
      <address>
        <city>Northport</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01047 Tucson Orhtopaedic Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01025 Martin, Bowen, Hefley Knee and Sports</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01053 OrthoArkansas, PA</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01085 Martin, Bowen, Hefley Knee and Sports</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01041 Core Orthopedic Medical Center</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01034 Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01005 Scripps Clinical Ctr for Orthopedic Rsrch &amp; Educ</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01077 Long Beach VA Healthcare system</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01064 Orthopedic Specialty Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01031 Colorodo Orthopedic Consultants, PC</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01027 Advanced Orthopedic and Sports Medicine Specialists, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01023 Orthopedic Physicians of Colorado, PC</name>
      <address>
        <city>Engelwood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01020 Bay Pines VA Medical Center</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01024 Pulmonary Associates of Brandon Clinical Research</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01030 Alliance Research, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01039 Florida Orthopedic Associates</name>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01036 Orthopaedic Associates of South Broward, PA</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01010 MIMA Century Research Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01062 Miami Institute for Joint Reconstruction</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01040 Southern Clinical Research Consultants</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01067 Baptist Clinical Research</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01029 Coastal Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01038 James A. Haley VA Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01063 Resurgens Orthopaedics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01072 Resurgeons Orthopedics</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01056 Southern Orthopaedic Specialists</name>
      <address>
        <city>Lawrencville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01028 Intermountain Research Center</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01022 Iowa Orthopedic Clinic</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01008 Bluegrass Orthopedic/Musculoskeletal Research, LLC</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01070 Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01007 Ortho Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01059 Rockhill Orthopaedics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01042 Center for Joint Care</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01014 Charlotte Orthopedic Specialists</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01035 Wellington Orthopedics and Sports Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01006 VA Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01044 Tulsa Bone and Joint Associates</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01002 The Orthopedic and Neurological Center of the Cascades</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01016</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01073 Coastal Orthopedic Associates, PA</name>
      <address>
        <city>Conway</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01032 Seton Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01003 Texas Orthopedic Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01090 VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01026 James Muntz, MD</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01033 Bone and Joint Clinic of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01076 Discovery Alliance</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01018 Gill Research Center</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01069 Correspondence and Pateint vists</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01015 Unlimited Research, LP</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01012 Anderson Orthopedic Clinic</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01052 Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01057 Orthopedic Specialty Clinic of Spokane, PLLC</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.01082 MultiCare Health System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02031 University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02036 2B2.37 Walter Mackenizie Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02024 Red Deer Regional Hospital</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02032 Kelowna General Hospital</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02034 Hematology/Oncology Research</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02025 Grace General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02007 Orthopaedics 4NE</name>
      <address>
        <city>Fredericton</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02027 Atlantic Health Sciences Corporation</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02021 Rouge Valley Health System</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02008 Orthopaedic Surgery</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02016 Orthopaedic Surgery</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02010 Joseph Brant Memorial Hospital</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02001 73 Delhi Street</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02014 565 Sanatorium Road</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02004 Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02028 NHS- Greater Niagara General Site</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02022 Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02017 1053 Carling Avenue</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02026 Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02015 York Central Hospital Research</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02009 2863 Ellesmere Road</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02029 Niagara Health System St. Catharine's General Site</name>
      <address>
        <city>St. Catherine's</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02003 46 General Hospital Drive</name>
      <address>
        <city>Stratford</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02033 Thunder Bay Regional Hospital</name>
      <address>
        <city>Thunder Bay</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02002 Toronto East General Hospital Fracture Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02023 North York General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02030 St. Joseph's Health Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02006 206-477 King Street</name>
      <address>
        <city>Welland</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02035 Humber River Regional Hospital</name>
      <address>
        <city>Weston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02011 Windsor Regional Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02012 Hotel Dieu Grace Hospital</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.02013 Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.05009 Traumatologia, Planta Baja</name>
      <address>
        <city>Guadalajara, Jalisco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.05004</name>
      <address>
        <city>México</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.24.44001 Ravenscourt Park Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>November 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 17, 2010</results_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The treatment period is from first administration of study medication, until 3 days after last administration of study medication. Treatment duration is planned for 12 - 15 days. The study period is from first administration of study medication until day 84 - 91.</recruitment_details>
      <pre_assignment_details>Whilst 2615 patients were enrolled/randomised to treatment post surgery in this trial, only 2596 started treatment. Therefore, 19 patients were randomised but not treated (treatment was planned to start post surgery).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="P2">
          <title>Dabigatran 150mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="P3">
          <title>Enoxaparin</title>
          <description>30mg bid (twice daily) subcutaneous</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="857"/>
                <participants group_id="P2" count="871"/>
                <participants group_id="P3" count="868"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="806">Non-completers in 'overall study' table may have completed treatment but not study, and vice versa</participants>
                <participants group_id="P2" count="823">Non-completers in 'overall study' table may have completed treatment but not study, and vice versa</participants>
                <participants group_id="P3" count="819">Non-completers in 'overall study' table may have completed treatment but not study, and vice versa</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="857"/>
                <participants group_id="P2" count="871"/>
                <participants group_id="P3" count="868"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="786">Non-completers in 'treatment' table may have completed study but not treatment, and vice versa</participants>
                <participants group_id="P2" count="808">Non-completers in 'treatment' table may have completed study but not treatment, and vice versa</participants>
                <participants group_id="P3" count="788">Non-completers in 'treatment' table may have completed study but not treatment, and vice versa</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="B2">
          <title>Dabigatran 150mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="B3">
          <title>Enoxaparin</title>
          <description>30mg bid (twice daily) subcutaneous</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="857"/>
            <count group_id="B2" value="871"/>
            <count group_id="B3" value="868"/>
            <count group_id="B4" value="2596"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="9.5"/>
                    <measurement group_id="B2" value="65.9" spread="9.5"/>
                    <measurement group_id="B3" value="66.3" spread="9.6"/>
                    <measurement group_id="B4" value="66.1" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="486"/>
                    <measurement group_id="B2" value="507"/>
                    <measurement group_id="B3" value="504"/>
                    <measurement group_id="B4" value="1497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="371"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="364"/>
                    <measurement group_id="B4" value="1099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.6" spread="6.0"/>
                    <measurement group_id="B2" value="31.4" spread="6.1"/>
                    <measurement group_id="B3" value="31.4" spread="6.0"/>
                    <measurement group_id="B4" value="31.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</title>
        <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
        <time_frame>First administration until 12-15 days</time_frame>
        <population>Full Analysis Set (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for distal and proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period</title>
          <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</description>
          <population>Full Analysis Set (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for distal and proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="604"/>
                <count group_id="O2" value="649"/>
                <count group_id="O3" value="643"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="219"/>
                    <measurement group_id="O3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority Analysis with NI margin 9.2% on the absolute risk difference scale</non_inferiority_desc>
            <p_value>0.0234</p_value>
            <p_value_desc>Hierarchical testing procedure: first non-inferiority, second superiority</p_value_desc>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>5.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>10.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority Analysis with NI margin 9.2% on the absolute risk difference scale</non_inferiority_desc>
            <p_value>0.0009</p_value>
            <p_value_desc>Hierarchical testing procedure: first non-inferiority, second superiority</p_value_desc>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>8.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>3.4</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</title>
        <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 12-15 days</time_frame>
        <population>Full Analysis Set - major (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died by a Venous Thromboembolic Event-related death)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period</title>
          <description>Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - major (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis, Pulmonary Embolism, or had died by a Venous Thromboembolic Event-related death)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="618"/>
                <count group_id="O2" value="656"/>
                <count group_id="O3" value="668"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2139</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>3.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3628</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</title>
        <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 12-15 days</time_frame>
        <population>Full Analysis Set - pDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period</title>
          <description>Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - pDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram for proximal Deep Vein Thrombosis, or had confirmed symptomatic Deep Vein Thrombosis)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="614"/>
                <count group_id="O2" value="656"/>
                <count group_id="O3" value="664"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2309</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0602</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</title>
        <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 12-15 days</time_frame>
        <population>Full Analysis Set - tDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram, or had confirmed symptomatic Deep Vein Thrombosis)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Deep Vein Thrombosis During Treatment Period</title>
          <description>Total Deep Vein Thrombosis as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - tDVT (all patients who had surgery and were randomised, received treatment, had an evaluable venogram, or had confirmed symptomatic Deep Vein Thrombosis)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="600"/>
                <count group_id="O2" value="648"/>
                <count group_id="O3" value="639"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="218"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0194</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>10.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Normal approximation</method>
            <method_desc>Normal approximation of independent binomial distribution without stratification</method_desc>
            <param_type>Risk Difference (Percentage)</param_type>
            <param_value>8.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.0</ci_lower_limit>
            <ci_upper_limit>13.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</title>
        <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 12-15 days</time_frame>
        <population>Full Analysis Set - op (all patients who are treated and operated)</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period</title>
          <description>Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op (all patients who are treated and operated)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="857"/>
                <count group_id="O2" value="871"/>
                <count group_id="O3" value="868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5774</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pulmonary Embolism During Treatment Period</title>
        <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 12-15 days</time_frame>
        <population>Full Analysis Set - op</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pulmonary Embolism During Treatment Period</title>
          <description>Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="857"/>
                <count group_id="O2" value="871"/>
                <count group_id="O3" value="868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7724</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0308</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died During Treatment Period</title>
        <description>All cause death, as adjudicated by the VTE events committee</description>
        <time_frame>First administration until 12-15 days</time_frame>
        <population>Full Analysis Set - op</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died During Treatment Period</title>
          <description>All cause death, as adjudicated by the VTE events committee</description>
          <population>Full Analysis Set - op</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="857"/>
                <count group_id="O2" value="871"/>
                <count group_id="O3" value="868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4968</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</title>
        <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
        <time_frame>3 months</time_frame>
        <population>Patients with any data available during follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period</title>
          <description>Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</description>
          <population>Patients with any data available during follow-up</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="840"/>
                <count group_id="O2" value="861"/>
                <count group_id="O3" value="853"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total VTE and all-cause mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asymptotic Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>symptotic Deep Vein Thrombosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</title>
        <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
        <time_frame>First administration until 12-15 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran 220mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O2">
            <title>Dabigatran 150mg</title>
            <description>qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>Enoxaparin</title>
            <description>30mg bid (twice daily) subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period</title>
          <description>Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</description>
          <population>Treated set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="857"/>
                <count group_id="O2" value="871"/>
                <count group_id="O3" value="868"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinically relevant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="783"/>
                    <measurement group_id="O2" value="799"/>
                    <measurement group_id="O3" value="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1416</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Comparison versus Enoxaparin</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0942</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First administration until (usually) day 21, i.e., treatment period + 3 days.</time_frame>
      <desc>Treatment emergent events (last medication + 3 days); The usual treatment period was 12 to 15 days with up to 18 days. Only one patient was treated for 33 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran 220mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="E2">
          <title>Dabigatran 150mg</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="E3">
          <title>Enoxaparin</title>
          <description>30mg bid (twice daily) subcutaneous</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Secretion discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Blister infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Occult blood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="718" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="724" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="711" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="268" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="245" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="198" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="189" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="244" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="275" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="254" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="157" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="167" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Post procedural oedema</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Post procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="67" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="79" subjects_at_risk="868"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="857"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="871"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="868"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

